Meticel

Celecoxib, the active ingredient in Meticel, is a COX‑2 inhibitor presented as an oral tablet for oral use. It provides anti‑inflammatory, analgesic and antipyretic effects for adults suffering from osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain and dysmenorrhea.

GNH USA supplies Meticel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Manufactured under EU GMP standards, the product meets European regulatory requirements and is distributed to health‑care providers across multiple continents. Its consistent purity and bioavailability support reliable clinical outcomes.

Celecoxib is a selective COX‑2 inhibitor used to manage inflammatory and painful conditions affecting the musculoskeletal system.

- Osteoarthritis: reduces joint pain and improves functional mobility in patients with degenerative joint disease. - Rheumatoid arthritis: alleviates inflammatory joint pain and swelling in adults with autoimmune arthritis. - Ankylosing spondylitis: decreases spinal stiffness and pain associated with chronic inflammatory back disease. - Acute pain: provides short‑term relief of moderate to severe pain from injuries or surgical procedures. - Dysmenorrhea: lessens menstrual cramps and associated pelvic discomfort in women.

Celecoxib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset or queasiness. - Headache: transient pain in the head region. - Hypertension: increase in blood pressure readings. - Edema: mild swelling of the ankles or feet. - Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects: - Cardiovascular events: increased risk of heart attack or stroke. - Gastrointestinal bleeding: ulceration or bleeding in the stomach or intestines. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Liver enzyme elevation: significant rise in ALT or AST levels. - Renal impairment: reduced kidney function or acute kidney injury.

Before prescribing celecoxib, clinicians should evaluate several safety considerations. - Cardiovascular risk assessment: review patient history of heart disease or stroke. - Blood pressure monitoring: check and record blood pressure regularly during therapy. - Gastro‑intestinal protection: consider ulcer prophylaxis in patients with prior GI bleeding. - Renal function evaluation: assess baseline kidney function and adjust use if impairment exists. - Hepatic safety: monitor liver enzymes periodically, especially in patients with liver disease. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Celecoxib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Lithium: can raise lithium serum concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors, diuretics): may reduce blood pressure control. - Methotrexate: potential for increased toxicity at high doses. - Cyclosporine: may elevate cyclosporine levels and nephrotoxicity.